José Garnacho-Montero
Seville, 41108, Spain
NCT Number: NCT03104933
This study evaluates the usefulness of pro-adrenomedullin (precursor of a vasodilatory peptide involved in septic shock pathogenesis) and copeptin (a stable peptide of the arginine vasopressin precursor) to predict, at the moment of septic shock diagnosis or their changes at 6 hours, the vasopressor requirements (measured by inotropic index and vasopressor dependency ratio) and volume requirement for resuscitation.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Seville, 41108, Spain
Physiologically, adrenomedullin has a potent and prolonged vasodilatory effect. In both experimental animals and humans, the intravenous administration of ADM induces a marked and prolonged hypotension. Serum ADM levels are elevated in patients with septic shock. In fact, ADM seems to be one of the main mediators involved in hypotension that these patients present.
ADM is not stable in plasma due to its short half-life and rapid binding to receptors. ADM levels can be measured indirectly by determining proadrenomedullin (proADM) which is a more stable molecule and whose levels are reflected in the plasma of ADM.
Copeptin is released primarily in response to changes in serum osmolarity or blood volume by increasing peripheral vascular resistance and blood pressure.
Copeptin is elevated in patients with shock of different etiologies such as hemorrhagic shock or septic shock.
It is not defined in what situations and at what moment an invasive monitoring of the cardiac output and the different hemodynamic variables that reflect the preload and afterload in patients with septic shock should be performed. In fact, there is great variability in the management and treatment of patients with sepsis and septic shock, which includes the selection of patients who require invasive monitoring and the time of onset.
Having a biomarker or the combination of biomarkers that allow early determination of which patients will evolve poorly with the development of a shock that requires volume in large quantities and high doses of vasopressors will allow identifying a subgroup of patients that should be performed early hemodynamic monitoring and intensify medical treatment to try to reverse these severe hemodynamic changes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: the first 72 hours.
measured by index inotropic and vasopressor dependency ratio) and fluid requirement
Time frame: the first 72 hours.
measured by index inotropic and vasopressor dependency ratio) and fluid requirement
Time frame: 28 days
SOFA scale
Time frame: 28 days
Mortality
Time frame: 6 hours
Lactate clearance
Spanish Network for Research in Infectious Diseases
Other
Proadrenomedullin and Copeptin as Predictors of Vasopressor Requirements and Volume Resuscitation in Patients With Septic Shock
Acronym: proADM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06953297
Critical Illness, Critical Illness Sepsis, Severe
Trabzon, Turkey (Türkiye)
View Trial DetailsNCT05506319
Diabetes Insipidus, Endocrine System Diseases
Porto Alegre, Rio Grande do Sul, Brazil
View Trial DetailsNCT03014063
Diabetes Insipidus, Endocrine System Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT00698048
Diabetes Insipidus, Endocrine System Diseases
Singapore
View Trial Details